Essa’s primary research efforts are focused on developing small molecule therapies to treat patients with androgen receptor (AR)-driven prostate cancer, with a focus on new treatment modalities targeting the N-terminal domain (NTD) of the AR. Our lead candidate, masofaniten (formerly EPI-7386), is a first-in-class NTD AR inhibitor (Aniten) that suppresses androgen biology through a novel mechanism of action. ESSA’s highly differentiated approach has the potential to bypass current AR-based resistance mechanisms that develop in patients with prostate cancer and to potentially expand the interval of time in which patients can benefit from anti-hormone-based therapies.